|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Mar 30, 2009. Current
Operations
Our business is organised into two business units:
Biopharmaceuticals and EDT. Biopharmaceuticals engages in
research, development and commercial activities primarily in
Alzheimer’s disease, Parkinson’s disease, multiple
sclerosis, Crohn’s disease, severe chronic pain and
infectious diseases. EDT is an established, profitable specialty
pharmaceutical business unit of Elan. For nearly 40 years,
EDT has been applying its skills and knowledge to enhance the
performance of dozens of drugs that have subsequently been
marketed worldwide. For additional information on our current
operations, please refer to the “Operating Review” on
pages 17 to 50.
This excerpt taken from the ELN 20-F filed Feb 26, 2009. CURRENT
OPERATIONS
Our business is organized into two business units:
Biopharmaceuticals and EDT. Biopharmaceuticals engages in
research, development and commercial activities primarily in
Alzheimer’s disease, Parkinson’s disease, multiple
sclerosis, Crohn’s disease, severe chronic pain and
infectious diseases. EDT is an established, profitable specialty
pharmaceutical business unit of Elan. For nearly 40 years,
EDT has been applying its skills and knowledge to enhance the
performance of dozens of drugs that have subsequently been
marketed worldwide. For additional information on our current
operations, refer to Item 4.B. “Business
Overview.”
This excerpt taken from the ELN 6-K filed Mar 31, 2008. Current
Operations
Our business is organised into two business units:
Biopharmaceuticals and EDT. Biopharmaceuticals engages in
research, development and commercial activities primarily in
Alzheimer’s disease, Parkinson’s disease, multiple
sclerosis, Crohn’s disease, severe chronic pain and
infectious diseases. EDT is an established, profitable and
growing specialty pharmaceutical business unit of Elan. For
nearly 40 years, EDT has been applying its skills and
knowledge to enhance the performance of dozens of drugs that
have been marketed worldwide.
For additional information on our current operations, please
refer to the “Operating Review” on pages 10 to 28.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. CURRENT
OPERATIONS
Our business is organized into two business units:
Biopharmaceuticals and EDT. Biopharmaceuticals engages in
research, development and commercial activities primarily in
Alzheimer’s disease, Parkinson’s disease, multiple
sclerosis, Crohn’s disease, severe chronic pain and
infectious diseases. EDT is an established, profitable and
Table of Contents
growing specialty pharmaceutical business unit of Elan. For
nearly 40 years, EDT has been applying its skills and
knowledge to enhance the performance of dozens of drugs that
have been marketed worldwide. For additional information on our
current operations, please refer to Item 4.B.
“Business Overview.”
This excerpt taken from the ELN 6-K filed Mar 30, 2007. Current
Operations
Our operations are organised into two business units:
Biopharmaceuticals and EDT. Biopharmaceuticals engages in
research, development and commercial activities and includes our
activities in the areas of autoimmune diseases,
neurodegenerative diseases and our specialty business group. EDT
focuses on product development,
scale-up and
manufacturing to address drug optimisation challenges of the
pharmaceutical industry.
For additional information on our current operations please
refer to the Operating Review on pages 4 to 28.
This excerpt taken from the ELN 20-F filed Feb 28, 2007. CURRENT
OPERATIONS
Our business is organized into two business units:
Biopharmaceuticals and EDT. Biopharmaceuticals engages in
research, development and commercial activities and includes our
activities in the areas of autoimmune diseases,
neurodegenerative diseases and our specialty business group. EDT
focuses on product development,
scale-up and
Table of Contents
manufacturing to address drug optimization challenges of the
pharmaceutical industry. For additional information on our
current operations, please refer to Item 4B on
pages 14 to 28.
This excerpt taken from the ELN 6-K filed Mar 31, 2006. Current Operations
Our business is organised into two business units:
Biopharmaceuticals and EDT. Biopharmaceuticals engages in
research, development and commercial activities and includes our
activities in the areas of autoimmune diseases,
neurodegenerative diseases, and our specialty business group.
EDT focuses on product development,
scale-up and
manufacturing to address drug optimisation challenges of the
pharmaceutical industry.
For additional information on our current operations please
refer to the Operating Review on pages 1 to 32.
This excerpt taken from the ELN 20-F filed Mar 30, 2006. CURRENT
OPERATIONS
Our business is organized into two business units:
Biopharmaceuticals and EDT. Biopharmaceuticals engages in
research, development and commercial activities and includes our
activities in the areas of autoimmune diseases,
neurodegenerative diseases and our specialty business group. EDT
focuses on product development,
scale-up and
manufacturing to address drug optimization challenges of the
pharmaceutical industry.
For additional information on our current operations, please
refer to Item 4 on pages 15 to 35.
| EXCERPTS ON THIS PAGE:
RELATED TOPICS for ELN: |
| |||||||
